Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc. (NASDAQ:ACTU) with a Buy rating and announced a price target of $20. Actuate Therapeutics shares …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc. (NASDAQ:ACTU) with a Buy rating and announced a price target of $20. Actuate Therapeutics shares …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc. (NASDAQ:ACTU) with a Buy rating and announced a price target of $20. Actuate Therapeutics shares …Full story available on Benzinga.com Read MoreACTU, CDNA, GYRE, Top Initiations, Initiation, Pre-Market Outlook, Markets, Analyst Ratings, ACTU, CDNA, GYRE, Initiation, Pre-Market Outlook, Markets, Analyst Ratings, Benzinga Markets
